Patients with Follicular Lymphoma
We Need Your Help!
Lymphoma Canada is preparing a submission for the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Quebec equivalent INESSS (Institut national d’excellence en santé et services sociaux), for an upcoming drug review on Axicabtagene Ciloleucel (Yescarta), a CAR T-cell therapy, for relapsed or refractory Follicular Lymphoma (FL).
If you have FL and have received this treatment, you can help by completing our survey! You can still participate in this survey if you have not received this therapy. You do not need to have relapsed or refractory FL to participate.
The survey provides us with patient input required for the submission. CADTH uses this information to help make recommendations to the provinces and territories regarding funding for new cancer drugs.
You do not need to live in Canada to complete this survey.
BY COMPLETING THIS SURVEY, YOU ARE PART OF THE PROCESS THAT MAY HELP PATIENTS GAIN ACCESS TO THIS TREATMENT IN CANADA.
The survey will be open until midnight Pacific Time on Monday, July 18, and should only take between 15-20 minutes of your time.
Please share and help us spread the word.
Thank you for your support.
Follow us on Social Media to stay up to date and informed on all things Lymphoma Canada!
